News headlines about Medical Transcription Billing, Corp. (NASDAQ:MTBC) have trended somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medical Transcription Billing, Corp. earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the technology company an impact score of 46.5907301541714 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media stories that may have effected Accern’s analysis:

Shares of Medical Transcription Billing, Corp. (MTBC) opened at 1.4501 on Wednesday. The company has a 50 day moving average price of $1.40 and a 200-day moving average price of $1.17. The firm’s market capitalization is $14.75 million. Medical Transcription Billing, Corp. has a 12 month low of $0.29 and a 12 month high of $3.84.

Medical Transcription Billing, Corp. (NASDAQ:MTBC) last announced its quarterly earnings data on Thursday, August 3rd. The technology company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.15. The firm had revenue of $7.79 million during the quarter. Medical Transcription Billing, Corp. had a negative return on equity of 59.52% and a negative net margin of 32.88%. Equities research analysts expect that Medical Transcription Billing, Corp. will post ($0.69) EPS for the current fiscal year.

A number of brokerages recently issued reports on MTBC. ValuEngine raised Medical Transcription Billing, Corp. from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Zacks Investment Research raised Medical Transcription Billing, Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, May 30th. Finally, Chardan Capital upped their target price on Medical Transcription Billing, Corp. from $1.85 to $2.25 and gave the company a “buy” rating in a research report on Monday, May 15th.

TRADEMARK VIOLATION WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dailypolitical.com/2017/08/09/medical-transcription-billing-corp-mtbc-receives-coverage-optimism-score-of-0-19.html.

Medical Transcription Billing, Corp. Company Profile

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.

Insider Buying and Selling by Quarter for Medical Transcription Billing, Corp. (NASDAQ:MTBC)

Receive News & Ratings for Medical Transcription Billing Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing Corp. and related companies with MarketBeat.com's FREE daily email newsletter.